TURCAN, SEVIN, Ph.D

GENERAL INFORMATION

Max-Eder Research Group Leader
Heidelberg University Hospital, Department of Neurology
Im Neuenheimer Feld 460
69120 Heidelberg, Germany

A04

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2004-2010	PhD, Biomedical Engineering, Tufts University
2002-2004	Master of Science, Biomedical Engineering, Tufts University
1998-2002	Bachelor of Science, Biomedical Engineering, Johns Hopkins University

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2004-2010	PhD, Biomedical Engineering, Tufts University Dissertation: Computational approaches to studying peripheral auditory system development and protection against ototoxicity Mentor: Douglas Vetter

PROFESSIONAL EXPERIENCE

Year(s)	Experience
2016 – Present	Max-Eder junior research group leader, Department of Neurology Heidelberg University Hospital
2010-2016	Postdoctoral fellow, Memorial Sloan Kettering Cancer Center

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	Qualifications/Roles/Responsibilities
2020-2023	DFG Research Grant
2019-2022	Baden-Württemberg Foundation Grant
2018-2021	Fritz-Thyssen Foundation Grant
2017-present	Max-Eder-Nachwuchsgruppe, Deutsche Krebshilfe
2016-2017	The Imaging and Radiation Sciences Program (IMRAS) Memorial Sloan Kettering Cancer Center
2015-2016	B*CURED award (Co-investigator, PI: Carl LeKaye)
2016-2018	Starr Cancer Consortium Grant (Investigator, PI: Je Lee)
2012-2014	NIH NRSA Postdoctoral Institutional Training Grant
2013	Memorial Sloan-Kettering Cancer Center Postdoctoral Researcher Award

SELECTED PUBLICATIONS

1. Cui H*, Sun X*, Schilling M, Herold-Mende Cc, Reischl M, Levkin PA, Popova AA, Turcan S. Drug repurposing by high-throughput miniaturized screening of IDH1 mutant glioma spheroids on droplet microarray chip. **Adv Healthc Mater**. 20223 May 10: e2300591. doi: 10.1002/adhm.202300591
2. Demirdizen E, Al-Ali R, Narayanan A, Sun X, Varga JP, Steffl B, Brom M, Krunic D, Schmidt C, Schmidt G, Bestvater F, Taranda J, Turcan S. TRIM67 drives tumorigenesis in oligodendrogliomas through Rho GTPase-dependent membrane blebbing. **Neuro Oncol**. 2023 Jun 2;25(6):1031-1043. doi: 10.1093/neuonc/noac233.

3. Schönrock A, Heinzelmann E, Steffl B, Narayanan A, Krunic D, Bähr M, Park JW, Schmidt C, Özduman K, Pamir MN, Wick W, Bestvater F, Weichenhan D, Plass C, Taranda J, Mall M, Turcan Ş. MEOX2 homeobox gene promotes growth of malignant gliomas **Neuro Oncol.** 2022 Apr 25:noac110. doi: 10.1093/neuonc/noac110
4. Park JW, Sahm F, Steffl B, Arrillaga-Romany I, Cahill D, Monje M, Herold-Mende C, Wick W, Turcan S. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. **Neuro Oncol**. 2020 Sep 3:noaa207. doi: 10.1093/neuonc/noaa207
5. Narayanan A, Demirdizen E, Blanco-Carmona E, Sun X, Schlesner M, Herold-Mende C, Turcan S*. Nuclei isolation from fresh frozen brain tumors for single-nucleus RNA-seq and ATAC-seq. **JoVE**. 2020 Aug 25. doi: 10.3791/61542
6. Turcan S, Makarov V, Taranda J, Wang Y, El-Amine N, Haddock S, Nanjangud G, LeKaye CH, Brennan C, Cross J, Huse JT, Kelleher NL, Osten P, Thompson CB, Chan TA. **Nature Genetics** 2018 Jan;50(1):62-72
7. Turcan S, Fabius AWM, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, and Chan TA, Efficient Induction of Differentiation and Growth Inhibition in IDH1 Mutant Glioma Cells by the DNMT Inhibitor Decitabine. **Oncotarget** 2013 Oct;4(10):1729-36
8. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, Mellinghoff IK. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. **Science**. 2013 May 3;340(6132):626-30
9. Turcan S, Rohle D, Goenka A, Walsh L, Fang F, Yilmaz E, Campos C, Fabius AWM, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LGT, Huse JT, Mellinghoff I, Chan TA. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. **Nature** 2012 Feb 15;483(7390):474-8
10. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, Thompson CB. IDH mutation impairs histone demethylation and results in a block to cell differentiation. **Nature** 2012 Feb 15;483(7390):474-8

PATENTS

- Timothy A. Chan, Fang Fang, Sevin Turcan. Epigenomic markers of cancer metastasis (US20140113286)